Prima implant enables sight for advanced AMD patients after training

Prima's implant helps patients with advanced age-related macular degeneration perform daily tasks after training, with EU approval pending US clearance

Prima's implant system, approved in Europe in July 2026, enables patients with advanced age-related macular degeneration (AMD) to read, complete crosswords, and use smartphones after training sessions. The system replaces damaged photoreceptors in the retina and has shown 80% of recipients achieve these functions post-training. While AMD affects over 5 million people globally, Prima targets only advanced cases with central blind spots where vision loss is severe enough to impact independence. The device is currently approved for use in Europe but remains pending FDA clearance in the United States. This advancement directly supports the SUSTENANCE and KNOWLEDGE sectors by restoring practical visual access for a specific subset of AMD patients who previously faced significant functional limitations.

The system moves abundance by reducing barriers to information access and social connection for those with advanced AMD, though it requires training and is not yet available in the U.S. Its efficacy is limited to patients with central blind spots, meaning it does not address all AMD cases or provide full vision restoration. The U.S. regulatory status and broader accessibility remain key watchpoints.

Source: MIT Tech Review